

Umberto Capitanio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2024162/publications.pdf>

Version: 2024-02-01

388
papers

15,400
citations

19657

61
h-index

29157

104
g-index

402
all docs

402
docs citations

402
times ranked

10719
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2022, 8, 182-190.	3.1	15
2	The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates. <i>World Journal of Urology</i> , 2022, 40, 1063-1064.	2.2	2
3	Predicting Complications After Robotic Partial Nephrectomy: Back to Simplicity. <i>European Urology Focus</i> , 2022, 8, 777-783.	3.1	7
4	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e1-10.e6.	1.6	20
5	Warm ischemia time length during on-clamp partial nephrectomy: does it really matter?. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	18
6	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. <i>European Urology Oncology</i> , 2022, 5, 125-133.	5.4	10
7	A Nomogram for the Prediction of Intermediate Significant Renal Function Loss After Robot-assisted Partial Nephrectomy for Localized Renal Tumors: A Prospective Multicenter Observational Study (RECORD2 Project). <i>European Urology Focus</i> , 2022, 8, 980-987.	3.1	12
8	Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	27
9	External validation of the Palacios™ equation: a simple and accurate tool to estimate the new baseline renal function after renal cancer surgery. <i>World Journal of Urology</i> , 2022, 40, 467-473.	2.2	10
10	Simplified PADUA renal (SPARE) nephrometry score validation and long-term outcomes after robot-assisted partial nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 65.e1-65.e9.	1.6	5
11	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. <i>European Journal of Surgical Oncology</i> , 2022, 48, 687-693.	1.0	12
12	Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action. <i>Current Opinion in Urology</i> , 2022, 32, 31-39.	1.8	3
13	Cytoreductive Nephrectomy in 2021: Obsolete but Necessary. <i>European Urology Open Science</i> , 2022, 36, 41-43.	0.4	3
14	Risk factors for progression of chronic kidney disease after robotic partial nephrectomy in elderly patients: results from a multi-institutional collaborative series. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	14
15	The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1840-1847.	1.0	3
16	Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification. <i>Kidney and Blood Pressure Research</i> , 2022, 47, 147-150.	2.0	2
17	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	1.9	29
18	Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 271.e19-271.e27.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	2.5	2
20	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	2.5	4
21	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. <i>European Urology</i> , 2022, 81, 476-488.	1.9	44
22	Is Hypertension Associated with Worse Renal Functional Outcomes after Minimally Invasive Partial Nephrectomy? Results from a Multi-Institutional Cohort. <i>Journal of Clinical Medicine</i> , 2022, 11, 1243.	2.4	6
23	Radiomic and gEnomic approaches for the enhanced Diagnosis of clear cell Renal Cancer (REDIRECT): a translational pilot methodological study. <i>Translational Andrology and Urology</i> , 2022, 11, 149-158.	1.4	3
24	Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>Eur Urol.</i> 2022;81:576â€“85.. <i>European Urology</i> , 2022, 81, e149.	1.9	3
25	Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities. <i>European Urology</i> , 2022, 81, 574-575.	1.9	7
26	Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martiniâ€™s nomogram on the RECORD2 project cohort. <i>International Journal of Urology</i> , 2022, 29, 525-532.	1.0	9
27	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. <i>Minerva Urology and Nephrology</i> , 2022, 74, 186-193.	2.5	9
28	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	1.9	485
29	Estimated Glomerular Filtration Rate Decline at 1 Year After Minimally Invasive Partial Nephrectomy: A Multimodel Comparison of Predictors. <i>European Urology Open Science</i> , 2022, 38, 52-59.	0.4	18
30	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Tj ETQq0 0 0 rgBT Overlock 10 Tf 50 29		
31	MO165: The Controversial Role of Proteinuria and Urinary Output After Radical Nephrectomy in the Development Of Acute Kidney Injury: Double Agents. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
32	MO155: The Importance of Measured GFR in Clinical Practice: An Old Knowledge for Nephrologists, a New Challenge for Oncologists and Surgeons. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
33	MO189: The Clinical Relevance of Measured GFR in Patients with Solitary Kidney after Radical Nephrectomy: The Estimation is not Enough. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
34	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	3.8	20
35	Reply to Sebastiano Buti and Giulia Claire Giudice's Letter to the Editor comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: Is AUC close enough to clinical practice? <i>Urol Oncol.</i> 2022 Apr 14:S1078-1439(22)00066-7. doi: 10.1016/j.urolonc.2022.02.015.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, . .	1.6	0
36	Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 384.e15-384.e21.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 384.e9-384.e14.	1.6	2
38	Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥ 10) Renal Tumors: A Prospective Multicenter Observational Study (the Tj ETQq0 0 0 ggBT /Overdeck 10 Tf		
39	Head to Head Impact of Margin, Ischemia, Complications, Score Versus a Novel Trifecta Score on Oncologic and Functional Outcomes After Robotic-assisted Partial Nephrectomy: Results of a Multicenter Series. <i>European Urology Focus</i> , 2021, 7, 1391-1399.	3.1	16
40	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	3.1	4
41	The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. <i>World Journal of Urology</i> , 2021, 39, 2553-2558.	2.2	12
42	Robotic-assisted Partial Nephrectomy for "Very Small" (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. <i>European Urology Focus</i> , 2021, 7, 1115-1120.	3.1	7
43	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. <i>European Urology Focus</i> , 2021, 7, 574-581.	3.1	30
44	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 829-833.	5.4	20
45	Toward Individualized Approaches to Partial Nephrectomy: Assessing the Correlation Between Ischemia Time and Patient Health Status (RECORD2 Project). <i>European Urology Oncology</i> , 2021, 4, 645-650.	5.4	13
46	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. <i>World Journal of Urology</i> , 2021, 39, 461-472.	2.2	15
47	Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. <i>World Journal of Urology</i> , 2021, 39, 1195-1201.	2.2	11
48	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	6.3	30
49	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 554-560.	6.4	10
50	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas. <i>Cancer Causes and Control</i> , 2021, 32, 119-126.	1.8	1
51	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1187-1190.	1.0	11
52	Editorial Comment from Dr Martini <i>et al</i> . to Independent external validation of a nomogram to define risk categories for a significant decline in estimated glomerular filtration rate after robotic-assisted partial nephrectomy. <i>International Journal of Urology</i> , 2021, 28, 80-81.	1.0	0
53	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery"Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	5.4	33
54	How to Select the Optimal Candidates for Renal Mass Biopsy. <i>European Urology Oncology</i> , 2021, 4, 506-509.	5.4	10

#	ARTICLE	IF	CITATIONS
55	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e15-235.e21.	1.6	10
56	Outcomes of robot-assisted partial nephrectomy for completely endophytic renal tumors: A multicenter analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1179-1186.	1.0	32
57	Is partial nephrectomy safe and effective in the setting of frail comorbid patients affected by renal cell carcinoma? Insights from the RECORD 2 multicentre prospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 78.e17-78.e26.	1.6	8
58	The Impact of Surgical Strategy in Robot-assisted Partial Nephrectomy: Is It Beneficial to Treat Anterior Tumours with Transperitoneal Access and Posterior Tumours with Retroperitoneal Access?. <i>European Urology Oncology</i> , 2021, 4, 112-116.	5.4	23
59	Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Eur Urol Focus</i> . In press. https://doi.org/10.1016/j.euf.2019.06.002 . <i>European Urology Focus</i> , 2021, 7, 406.	3.1	0
60	Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project). <i>European Urology Focus</i> , 2021, 7, 390-396.	3.1	63
61	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1369-1376.	2.2	34
62	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 22-41.	5.4	33
63	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3377-3383.	2.2	5
64	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. <i>European Urology</i> , 2021, 80, 575-588.	1.9	48
65	Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. <i>International Journal of Cancer</i> , 2021, 149, 186-190.	5.1	6
66	How to improve outcome in nephron-sparing surgery: the impact of new techniques. <i>Current Opinion in Urology</i> , 2021, 31, 255-261.	1.8	7
67	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 339-342.	1.9	98
68	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 3823-3831.	2.2	2
69	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021, 128, 386-394.	2.5	5
70	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, .	5.4	6
71	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 1292-1292.	0.4	0
72	Retroperitoneal versus transepritoneal robot-assisted partial nephrectomy for postero-lateral renal masses: an international multicenter analysis. <i>World Journal of Urology</i> , 2021, 39, 4175-4182.	2.2	11

#	ARTICLE	IF	CITATIONS
73	Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. <i>European Urology</i> , 2021, 80, 730-737.	1.9	12
74	High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?. <i>Current Problems in Cancer</i> , 2021, 45, 100759.	2.0	5
75	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	5.4	0
76	B2B: Kidney Cancer Summary. <i>Societ� Internationale D'urologie Journal</i> , 2021, 2, S19-S28.	0.4	0
77	Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects. <i>Journal of Clinical Medicine</i> , 2021, 10, 3322.	2.4	5
78	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	1.9	17
79	Outcomes in robot-assisted partial nephrectomy for imperative vs elective indications. <i>BJU International</i> , 2021, 128, 30-35.	2.5	7
80	Renal cancer: overdiagnosis and overtreatment. <i>World Journal of Urology</i> , 2021, 39, 2821-2823.	2.2	11
81	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. <i>BJU International</i> , 2021, 128, 722-727.	2.5	13
82	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. <i>Surgical Oncology</i> , 2021, 38, 101588.	1.6	8
83	Robot-assisted partial nephrectomy: 7-year outcomes. <i>Minerva Urology and Nephrology</i> , 2021, 73, 540-543.	2.5	43
84	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	1.9	103
85	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 962-970.	2.2	4
86	Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium. <i>World Journal of Urology</i> , 2021, 39, 2969-2975.	2.2	9
87	Parenchymal biopsy in the management of patients with renal cancer. <i>World Journal of Urology</i> , 2021, 39, 2961-2968.	2.2	14
88	External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88). <i>European Urology Open Science</i> , 2021, 33, 89-93.	0.4	9
89	Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>N Engl J Med</i> 2021;385:683-94. <i>European Urology</i> , 2021, 81, e28-e28.	1.9	4
90	Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REal SURGery in Elderly (RESURGE) Group. <i>European Urology Focus</i> , 2020, 6, 982-990.	3.1	20

#	ARTICLE	IF	CITATIONS
91	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	2.2	23
92	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. <i>European Urology Oncology</i> , 2020, 3, 209-215.	5.4	37
93	Renal surgery for the older population: time for a paradigm shift? Data from the RESURGE project. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 173-178.	2.9	5
94	Percutaneous Microwave Ablation Versus Cryoablation in the Treatment of T1a Renal Tumors. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 76-83.	2.0	23
95	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	1.9	228
96	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	1.9	75
97	Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. <i>Urology</i> , 2020, 138, 60-68.	1.0	20
98	Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. <i>Cancers</i> , 2020, 12, 3345.	3.7	3
99	Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. <i>Urology</i> , 2020, 146, 125-132.	1.0	9
100	Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2) <i>TJ ETQq0 0 0 zgt /Overclock 10 Tf</i>		
101	Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery. <i>IEEE Transactions on Medical Robotics and Bionics</i> , 2020, 2, 148-156.	3.2	10
102	Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 523-529.	5.4	33
103	Reply to Vincenzo Ficarra, Giuseppe Mucchiardi, and Gianluca Giannarini's Letter to the Editor re: Riccardo Campi, Daniele Amparore, Umberto Capitanio, et al. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. <i>Eur Urol</i> 2020;78:11â€“15. <i>European Urology</i> , 2020, 78, e168-e170.	1.9	1
104	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. <i>European Urology</i> , 2020, 78, 321-326.	1.9	25
105	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	1.9	128
106	Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 521-525.	1.6	5
107	Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e723-e729.	1.9	28
108	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 537-544.	1.6	13

#	ARTICLE	IF	CITATIONS
109	Upstaging to pT3a disease in patients undergoing robotic partial nephrectomy for cT1 kidney cancer: Outcomes and predictors from a multi-institutional dataset. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 286-292.	1.6	15
110	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T ₂₋₄ Renal Masses. <i>Journal of Endourology</i> , 2020, 34, 289-297.	2.1	9
111	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 688-696.	1.7	19
112	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 166-179.	2.0	11
113	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. <i>BJU International</i> , 2020, 126, 114-123.	2.5	42
114	Predicting intraoperative and postoperative consequential events using machine-learning techniques in patients undergoing robot-assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. <i>BJU International</i> , 2020, 126, 350-358.	2.5	14
115	Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. <i>European Urology</i> , 2020, 78, 11-15.	1.9	84
116	Chronic Kidney Disease After Partial Nephrectomy in Patients With Preoperative Inconspicuous Renal Function – Curiosity or Relevant Issue?. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e754-e761.	1.9	16
117	Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORD 2 project). <i>European Journal of Surgical Oncology</i> , 2020, 46, 1353-1359.	1.0	16
118	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2020, 203, 496-504.	0.4	61
119	Surgical quality, cancer control and functional preservation: introducing a novel trifecta for robot-assisted partial nephrectomy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 82-90.	3.9	45
120	Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 99-108.	3.9	28
121	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. <i>Minerva Urology and Nephrology</i> , 2020, , .	2.5	9
122	Comprehensive long-term assessment of outcomes following robot-assisted partial nephrectomy for renal cell carcinoma: the ROME's achievement and its predicting nomogram. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 482-489.	3.9	24
123	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2020, , .	2.5	3
124	Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 389-407.	3.9	26
125	Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study. <i>Central European Journal of Urology</i> , 2020, 73, 33-38.	0.3	3
126	Outcomes of minimally invasive partial nephrectomy among very elderly patients: report from the RESURGE collaborative international database. <i>Central European Journal of Urology</i> , 2020, 73, 273-279.	0.3	4

#	ARTICLE	IF	CITATIONS
127	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1
128	MP21-02â€fTHE IMPACT OF INTRAOPERATIVE BLEEDING ON THE RISK OF CHRONIC KIDNEY DISEASE AFTER NEPHRON-SPARING SURGERY. Journal of Urology, 2020, 203, .	0.4	2
129	Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma. World Journal of Urology, 2019, 37, 701-708.	2.2	4
130	Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?. European Urology, 2019, 76, 441-442.	1.9	6
131	Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. European Urology Oncology, 2019, 2, 572-575.	5.4	43
132	SP236THE RADICAL NEPHRECTOMY PARADOX: THE UNEXPECTED AKI'S RISK. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
133	SP267RENAL HISTOLOGY VERSUS ESTIMATED GLOMERULAR FILTRATION RATE: BEYOND THE LOOKING GLASS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
134	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	2.4	8
135	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. International Urology and Nephrology, 2019, 51, 2181-2188.	1.4	12
136	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Scientific Reports, 2019, 9, 13218.	3.3	14
137	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	5.4	38
138	The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 293.e25-293.e30.	1.6	10
139	Reply from Authors re: Jens. J. Rassweiler, Marcel Fiedler-Hruza. The Learning Curve for Robot-assisted Partial Nephrectomy: There is Much Beyond a Trifecta. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.022 . European Urology, 2019, 75, 259-260.	1.9	1
140	Should partial nephrectomy be considered â€œelectiveâ€•in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy. World Journal of Urology, 2019, 37, 2429-2437.	2.2	14
141	Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy. BJU International, 2019, 124, 6-7.	2.5	2
142	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	1.0	18
143	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.2	47
144	Virtual Reality Validation of the ERUS Simulation-based Training Programmes: Results from a High-volume Training Centre for Robot-assisted Surgery. European Urology, 2019, 75, 885-887.	1.9	22

#	ARTICLE	IF	CITATIONS
145	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). <i>Urology</i> , 2019, 129, 139-145.	1.0	9
146	The ERUS Curriculum for Robot-assisted Partial Nephrectomy: Structure Definition and Pilot Clinical Validation. <i>European Urology</i> , 2019, 75, 1023-1031.	1.9	64
147	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 1942-1949.	1.5	13
148	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. <i>Journal of Endourology</i> , 2019, 33, 438-447.	2.1	41
149	Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. <i>Eur Urol</i> 2018;74:661-7 and 2019:75:198. <i>European Urology</i> , 2019, 76, e17-e18.	1.9	0
150	Postoperative complications increase the risk of long-term chronic kidney disease after nephron-sparing surgery in patients with renal cancer and normal preoperative renal function. <i>BJU International</i> , 2019, 124, 457-461.	2.5	4
151	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq1 1 0.784314 rgBT /Overlock 107	2.25	36
152	Acute kidney injury after partial nephrectomy: transient or permanent kidney damage? – Impact on long-term renal function. <i>Annals of Translational Medicine</i> , 2019, 7, S317-S317.	1.7	7
153	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	5.4	73
154	Re: Ricardo G. Alvim, François Audenet, Emily A. Vertosick, Daniel D. Sjoberg, Karim A. Touijer. Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. <i>Eur Urol Oncol</i> 2018;1:428-34. <i>European Urology Oncology</i> , 2019, 2, 228-229.	5.4	0
155	Suture techniques during laparoscopic and robot-assisted partial nephrectomy: a systematic review and quantitative synthesis of perioperative outcomes. <i>BJU International</i> , 2019, 123, 923-946.	2.5	50
156	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1631-1637.	2.2	5
157	The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1623-1629.	2.2	7
158	Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 33-39.	1.6	18
159	Nomogram for predicting the likelihood of postoperative surgical complications in patients treated with partial nephrectomy: a prospective multicentre observational study (the <scp>RECOR</scp> d 2) Tj ETQq1 1 0.784314 rgBT /Overlock 107	2.25	36
160	Sildenafil: An Update on Efficacy, Safety and Clinical Indications in Urology. <i>Advances in Therapy</i> , 2019, 36, 1-18.	2.9	14
161	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. <i>Urologia Internationalis</i> , 2019, 102, 51-59.	1.3	4
162	Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinary Is Still Far Away. <i>European Urology</i> , 2019, 75, 349-350.	1.9	12

#	ARTICLE	IF	CITATIONS
163	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 74-84.	1.9	917
164	The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes. <i>European Urology</i> , 2019, 75, 253-256.	1.9	104
165	The Association of Uromodulin Genotype with Renal Cancer Aggressiveness. <i>European Urology Focus</i> , 2019, 5, 262-265.	3.1	4
166	Techniques and outcomes of minimally-invasive surgery for nonmetastatic renal cell carcinoma with inferior vena cava thrombosis: a systematic review of the literature. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 339-358.	3.9	37
167	Editorial Comment. <i>Journal of Urology</i> , 2019, 201, 1096-1096.	0.4	0
168	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e9-239.e15.	1.6	6
169	Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 200, 61-67.	0.4	11
170	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 176-183.	1.9	16
171	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. <i>Journal of Urology</i> , 2018, 199, 1143-1148.	0.4	46
172	Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study. <i>Urology</i> , 2018, 113, 85-90.	1.0	17
173	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. <i>BJU International</i> , 2018, 121, 684-698.	2.5	79
174	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e903-e908.	1.9	16
175	Comparison of functional outcomes of robotic and open partial nephrectomy in patients with pre-existing chronic kidney disease: a multicenter study. <i>World Journal of Urology</i> , 2018, 36, 1255-1262.	2.2	8
176	Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. <i>European Urology Focus</i> , 2018, 4, 435-441.	3.1	31
177	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 834-841.	3.1	7
178	â€˜Trifectaâ€™ outcomes of robot-assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis. <i>BJU International</i> , 2018, 121, 119-123.	2.5	27
179	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018, 4, 972-977.	3.1	12
180	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018, 36, 51-57.	2.2	16

#	ARTICLE	IF	CITATIONS
181	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT ≤ 2 non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	2.5	30
182	Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. <i>Journal of Urology</i> , 2018, 199, 66-73.	0.4	58
183	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. <i>European Urology</i> , 2018, 73, 793-799.	1.9	33
184	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	1.6	14
185	Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery. <i>European Urology Oncology</i> , 2018, 1, 538-539.	5.4	1
186	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	5.4	30
187	The Role of Ablation and Minimally Invasive Techniques in the Management of Small Renal Masses. <i>European Urology Oncology</i> , 2018, 1, 395-402.	5.4	30
188	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	1.9	19
189	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). <i>European Urology</i> , 2018, 74, 226-232.	1.9	109
190	Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. <i>Anticancer Research</i> , 2018, 38, 4123-4130.	1.1	6
191	mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 24, 1093-1104.e6.	6.4	20
192	The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Frontiers in Surgery</i> , 2018, 5, 26.	1.4	12
193	Retroperitoneal vs Transperitoneal Robot-assisted Partial Nephrectomy: Comparison in a Multi-institutional Setting. <i>Urology</i> , 2018, 120, 131-137.	1.0	59
194	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. <i>Urology</i> , 2018, 122, 152-157.	1.0	36
195	You Can Trust a Crystal Ball About as Far as You Can Throw It. <i>European Urology</i> , 2018, 73, 781-782.	1.9	2
196	Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 661-667.	1.9	84
197	Role of Active Surveillance for Localized Small Renal Masses. <i>European Urology Oncology</i> , 2018, 1, 177-187.	5.4	85
198	Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. <i>European Urology Oncology</i> , 2018, 1, 61-68.	5.4	38

#	ARTICLE	IF	CITATIONS
199	Robot-Assisted Partial Nephrectomy for Multiple Renal Tumors: A Vattikuti Collective Quality Initiative Database Analysis. <i>Videourology (New Rochelle, N Y)</i> , 2018, 32, .	0.1	1
200	The rationale and the role of lymph node dissection in renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 497-506.	2.2	37
201	Time of onset of vardenafil orodispersible tablet in a real-life setting â€“ looking beyond randomized clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-6.	3.1	6
202	Partial Nephrectomy for Large or Complex Masses: Option or Obsolete?. <i>European Urology</i> , 2017, 72, 76-77.	1.9	5
203	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq1 1 0.784314.orgBT /Overlock 10	1.0	11
204	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. <i>Urology</i> , 2017, 102, 130-137.	1.0	11
205	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging. <i>Urology</i> , 2017, 110, 114-120.	1.0	5
206	MP59-05 CRITICAL ANALYSIS AND ASSESSMENT OF CLINICAL UTILITY OF NEPHROMETRY SCORES FOR THE PREDICTION OF COMPLICATIONS AFTER NEPHRON SPARING SURGERY. <i>Journal of Urology</i> , 2017, 197, .	0.4	2
207	Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinomaâ€”Results of a Comprehensive Multicenter Study. <i>Urology</i> , 2017, 109, 107-114.	1.0	2
208	European temporal trends in the use of lymph node dissection in patients with renal cancer. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2184-2192.	1.0	20
209	Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 662.e9-662.e15.	1.6	11
210	When to perform preoperative chest computed tomography for renal cancer staging. <i>BJU International</i> , 2017, 120, 490-496.	2.5	11
211	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. <i>World Journal of Urology</i> , 2017, 35, 1031-1036.	2.2	14
212	Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. <i>Lancet Oncol Lancet</i> 2016;17:1317â€“24. <i>European Urology</i> , 2017, 71, e139-e140.	1.9	3
213	Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. <i>PLoS ONE</i> , 2017, 12, e0184173.	2.5	28
214	Populationâ€“based assessment of cancerâ€“specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. <i>BJU International</i> , 2016, 118, 541-546.	2.5	15
215	End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline. <i>European Urology</i> , 2016, 70, 558-561.	1.9	44
216	Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. <i>Journal of Urology</i> , 2016, 196, 1008-1013.	0.4	57

#	ARTICLE	IF	CITATIONS
217	Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. <i>European Urology Focus</i> , 2016, 1, 272-281.	3.1	33
218	Against the Role of Inflammatory Markers in Renal Cell Carcinoma Prognosis: The Missing Link Between Evidence of Association and Clinical Applicability. <i>European Urology Focus</i> , 2016, 2, 343-344.	3.1	1
219	Reply from Authors re: Steven C. Campbell, Wen Dong, Joe Zabell, Diego Aguilar Palacios. End-stage Renal Disease After Renal Surgery: Partial Nephrectomy Is Protective, but to What Degree and Consequence? <i>Eur Urol</i> 2016;70:562-3. <i>European Urology</i> , 2016, 70, 564-565.	1.9	0
220	MP41-11 RESECTION TECHNIQUES FOR NEPHRON SPARING SURGERY (NSS) VARY: INSIGHTS FROM A PROSPECTIVELY COLLECTED MULTI-INSTITUTIONAL COHORT HARNESSING THE SURFACE-INTERMEDIATE-BASE (S.I.B.) MARGIN SCORE (SIB INTERNATIONAL CONSORTIUM). <i>Journal of Urology</i> , 2016, 195, .	0.4	2
221	Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a-T1b Renal Mass and Normal Preoperative Renal Function. <i>Eur Urol.</i> 2016;69:538. <i>European Urology</i> , 2016, 70, e135.	1.9	0
222	Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1037-1045.	0.8	21
223	Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?. <i>European Urology</i> , 2016, 70, 899-900.	1.9	0
224	Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. <i>World Journal of Urology</i> , 2016, 34, 1139-1145.	2.2	19
225	Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?. <i>Journal of Endourology</i> , 2016, 30, 400-405.	2.1	17
226	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>Journal of Surgical Oncology</i> , 2016, 114, 764-768.	1.7	26
227	Lymph node dissection for renal cell carcinoma. <i>Current Opinion in Urology</i> , 2016, 26, 424-431.	1.8	11
228	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016, 195, 1354-1361.	0.4	30
229	Current Status of Focal Cryoablation for Small Renal Masses. <i>Urology</i> , 2016, 90, 9-15.	1.0	17
230	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. <i>European Urology</i> , 2016, 70, 429-435.	1.9	16
231	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. <i>European Journal of Cancer</i> , 2016, 54, 27-34.	2.8	26
232	Renal cancer. <i>Lancet, The</i> , 2016, 387, 894-906.	13.7	762
233	Long-term recovery of normal sexual function in testicular cancer survivors. <i>Asian Journal of Andrology</i> , 2016, 18, 85.	1.6	18
234	Factors predicting renal function after partial nephrectomy: A multi-institutional analysis of data from the SIB working group.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16063-e16063.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?. <i>Annals of Translational Medicine</i> , 2016, 4, 291-291.	1.7	1
236	Repeat Prostate Biopsy: Rationale, Indications, and Strategies. <i>European Urology Focus</i> , 2015, 1, 127-136.	3.1	12
237	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. <i>BJU International</i> , 2015, 116, 366-372.	2.5	4
238	Renal Tumor Biopsy: More Dogma Belied. <i>European Urology</i> , 2015, 68, 1014-1015.	1.9	15
239	Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1aâ€“T1b Renal Mass and Normal Preoperative Renal Function. <i>European Urology</i> , 2015, 67, 683-689.	1.9	202
240	Re: Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter, International Retrospective Cohort. <i>European Urology</i> , 2015, 67, 974-975.	1.9	2
241	Peyronie's Disease and Autoimmunityâ€”A Real-Life Clinical Study and Comprehensive Review. <i>Journal of Sexual Medicine</i> , 2015, 12, 1062-1069.	0.6	24
242	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. <i>European Urology</i> , 2015, 67, 212-219.	1.9	178
243	Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs. <i>World Journal of Urology</i> , 2015, 33, 873-880.	2.2	16
244	Repeated biopsy in the detection of prostate cancer: When and how many cores. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 311.	0.8	5
245	Onset of hydronephrosis and lower urinary tract symptoms in a previously healthy young man: Phylloides tumour of the prostate as a potential diagnosis.. <i>Canadian Urological Association Journal</i> , 2014, 8, 561.	0.6	4
246	Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 719-732.	1.9	20
247	Extent of lymph node dissection at nephrectomy affects cancerâ€“specific survival and metastatic progression in specific subâ€“categories of patients with renal cell carcinoma (<scp>RCC</scp>). <i>BJU International</i> , 2014, 114, 210-215.	2.5	69
248	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 546-551.	1.9	81
249	The Number of Cores at First Biopsy Mayâ€“Suggest the Need for a Confirmatory Biopsy in Patients Eligible for Active Surveillanceâ€”Implication for Clinical Decision Making in the Real-life Setting. <i>Urology</i> , 2014, 84, 634-641.	1.0	8
250	Random biopsy: when, how many and where to take the cores?. <i>World Journal of Urology</i> , 2014, 32, 859-869.	2.2	30
251	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: Conditional survival analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 43.e9-43.e16.	1.6	11
252	Radical prostatectomy represents an effective treatment in patients with specimenâ€“confined high pathological <scp>G</scp>leason score prostate cancer. <i>BJU International</i> , 2013, 111, 723-730.	2.5	25

#	ARTICLE	IF	CITATIONS
253	Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. <i>BJU International</i> , 2013, 111, 412-418.	2.5	19
254	Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. <i>BJU International</i> , 2013, 111, 717-722.	2.5	108
255	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. <i>BJU International</i> , 2013, 112, E59-66.	2.5	42
256	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. <i>World Journal of Urology</i> , 2013, 31, 275-280.	2.2	31
257	Editorial Comment to Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. <i>International Journal of Urology</i> , 2013, 20, 380-381.	1.0	0
258	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. <i>International Journal of Urology</i> , 2013, 20, 413-419.	1.0	21
259	The Number of Cores Taken in Patients Diagnosed with a Single Microfocus at Initial Biopsy is a Major Predictor of Insignificant Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 854-859.	0.4	19
260	Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy. <i>Journal of Urology</i> , 2013, 190, 496-501.	0.4	87
261	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1497-1503.	1.6	13
262	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , 2013, 63, 998-1008.	1.9	107
263	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. <i>World Journal of Urology</i> , 2013, 31, 267-273.	2.2	8
264	Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. <i>International Journal of Urology</i> , 2013, 20, 572-579.	1.0	22
265	Secondary Provoked Vestibulodynia in Sexually Active Women with Uncomplicated Recurrent Urinary Tract Infections. <i>Journal of Sexual Medicine</i> , 2013, 10, 2265-2273.	0.6	21
266	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. <i>BJU International</i> , 2013, 112, E234-42.	2.5	1
267	Prediction of delayed graft function after renal transplantation. <i>Canadian Urological Association Journal</i> , 2013, 3, 377.	0.6	39
268	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012, 4, 347-365.	2.0	12
269	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 3648-3657.	7.0	62
270	Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. <i>Urologia Internationalis</i> , 2012, 89, 126-135.	1.3	25

#	ARTICLE	IF	CITATIONS
271	Is Erectile Dysfunction a Reliable Proxy of General Male Health Status? The Case for the International Index of Erectile Functionâ€™Erectile Function Domain. <i>Journal of Sexual Medicine</i> , 2012, 9, 2708-2715.	0.6	92
272	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 533-539.	2.2	6
273	Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 624-629.	0.8	29
274	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. <i>Journal of Urology</i> , 2012, 187, 569-574.	0.4	35
275	Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. <i>Journal of Urology</i> , 2012, 188, 84-90.	0.4	28
276	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 252-258.	1.6	88
277	National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 423-428.	0.4	23
278	The Extent of Lymphadenectomy does Affect Cancer Specific Survival in Pathologically Confirmed T4 Renal Cell Carcinoma. <i>Urologia</i> , 2012, 79, 109-115.	0.7	26
279	Lymphatic spread of nodal metastases in highâ€™risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. <i>Prostate</i> , 2012, 72, 186-192.	2.3	79
280	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. <i>Prostate</i> , 2012, 72, 499-506.	2.3	14
281	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. <i>Prostate</i> , 2012, 72, 925-930.	2.3	12
282	Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. <i>European Urology</i> , 2012, 61, 480-487.	1.9	594
283	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2012, 61, 1132-1138.	1.9	120
284	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2012, 9, 608-617.	0.6	35
285	Erectile Function Outcome after Bilateral Nerve Sparing Radical Prostatectomy: Which Patients May Be Left Untreated?. <i>Journal of Sexual Medicine</i> , 2012, 9, 903-908.	0.6	31
286	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€™Sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2012, 9, 2187-2194.	0.6	17
287	Leydig cell tumor of the spermatic cord in an adolescent affected by congenital adrenal hyperplasia. <i>International Journal of Urology</i> , 2012, 19, 954-956.	1.0	4
288	Influence of obesity on tumour volume in patients with prostate cancer. <i>BJU International</i> , 2012, 109, 678-684.	2.5	26

#	ARTICLE	IF	CITATIONS
289	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasoundâ€gguided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU International, 2012, 110, E64-8.	2.5	34
290	Ageâ€adjusted validation of the most stringent criteria for active surveillance in lowâ€risk prostate cancer patients. Cancer, 2012, 118, 973-980.	4.1	25
291	GSU: misclassification or biological progression?. Nature Reviews Urology, 2011, 8, 65-66.	3.8	4
292	Contemporary management of patients with T1a and T1b prostate cancer. Current Opinion in Urology, 2011, 21, 252-256.	1.8	10
293	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 2011, 107, 1095-1101.	2.5	58
294	Sex hormoneâ€binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU International, 2011, 107, 1243-1249.	2.5	11
295	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU International, 2011, 108, 366-371.	2.5	31
296	The extent of tumour fat invasion affects survival in patients with renal cell carcinoma and venous tumour thrombosis. BJU International, 2011, 108, no-no.	2.5	13
297	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU International, 2011, 108, 1769-1775.	2.5	20
298	When should we expect no residual tumor (pT0) once we submit incidental T1aâ€b prostate cancers to radical prostatectomy?. International Journal of Urology, 2011, 18, 148-153.	1.0	19
299	Editorial Comment to Risk factors for pelvic lymphocoeles postâ€radical prostatectomy. International Journal of Urology, 2011, 18, 644-645.	1.0	5
300	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Sexual Medicine, 2011, 8, 1210-1217.	0.6	38
301	Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2â€4 pN+ Prostate Cancer: Results of a Matched Analysis. European Urology, 2011, 59, 832-840.	1.9	180
302	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. European Urology, 2011, 60, 75-77.	1.9	9
303	Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma. European Urology, 2011, 60, 358-365.	1.9	39
304	The Optimal Rebiopsy Prostatic Scheme Depends on Patient Clinical Characteristics: Results of a Recursive Partitioning Analysis Based on a 24-Core Systematic Scheme. European Urology, 2011, 60, 834-841.	1.9	32
305	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	1.9	209
306	Lymph Node Dissection in Renal Cell Carcinoma. European Urology, 2011, 60, 1212-1220.	1.9	120

#	ARTICLE	IF	CITATIONS
307	Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. <i>Cancer</i> , 2011, 117, 3953-3962.	4.1	47
308	Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. <i>Cancer</i> , 2011, 117, 5029-5038.	4.1	35
309	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 342-348.	0.8	93
310	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. <i>European Urology</i> , 2010, 57, 300-309.	1.9	159
311	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2010, 57, 575-581.	1.9	154
312	When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. <i>European Urology</i> , 2010, 57, 551-558.	1.9	137
313	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. <i>Journal of Sexual Medicine</i> , 2010, 7, 2521-2531.	0.6	102
314	Predictive models before and after radical prostatectomy. <i>Prostate</i> , 2010, 70, 1371-1378.	2.3	27
315	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	2.5	69
316	A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. <i>BJU International</i> , 2010, 105, 359-364.	2.5	48
317	A delay in radical nephroureterectomy can lead to upstaging. <i>BJU International</i> , 2010, 105, 812-817.	2.5	90
318	Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. <i>BJU International</i> , 2010, 105, 1548-1552.	2.5	49
319	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010, 105, 1402-1412.	2.5	132
320	A Nomogram Predicting Prostate Cancer-Specific Mortality after Radical Prostatectomy. <i>Urologia Internationalis</i> , 2010, 84, 132-140.	1.3	23
321	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 68-75.	0.4	146
322	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. <i>Journal of Urology</i> , 2010, 183, 2165-2170.	0.4	186
323	Nephron-sparing Surgery Is Equally Effective to Radical Nephrectomy for T1BNOMO Renal Cell Carcinoma: A Population-based Assessment. <i>Urology</i> , 2010, 75, 271-275.	1.0	98
324	A Population-based Comparison of Cancer-control Rates Between Radical and Partial Nephrectomy for T1A Renal Cell Carcinoma. <i>Urology</i> , 2010, 76, 883-888.	1.0	61

#	ARTICLE	IF	CITATIONS
325	Biopsy Schemes with the Fewest Cores for Detecting 95% of the Prostate Cancers Detected by a 24-Core Biopsy. <i>European Urology</i> , 2010, 57, 1-8.	1.9	94
326	Thirty-Day Mortality After Transurethral Resection of the Prostate in Patients Treated with Androgen Deprivation Therapy. <i>Journal of Endourology</i> , 2009, 23, 1347-1352.	2.1	3
327	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	6.3	144
328	A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 1013-1018.	7.0	34
329	Editorial Comment on: Prostate Growth and Prevalence of Prostate Diseases in Early Onset Spinal Cord Injuries. <i>European Urology</i> , 2009, 56, 149-150.	1.9	1
330	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. <i>European Urology</i> , 2009, 55, 617-628.	1.9	25
331	Suspected Clinical T3 Prostate Cancer Is Associated with a High Rate of Negative Extended Biopsies: Clinical Implications. <i>European Urology</i> , 2009, 55, 253-254.	1.9	3
332	A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 287-295.	1.9	121
333	Thirty-Day Mortality After Nephrectomy: Clinical Implications for Informed Consent. <i>European Urology</i> , 2009, 56, 998-1005.	1.9	60
334	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. <i>European Urology</i> , 2009, 56, 1-9.	1.9	161
335	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. <i>European Urology</i> , 2009, 56, 512-519.	1.9	143
336	Radical versus partial nephrectomy. <i>Cancer</i> , 2009, 115, 1465-1471.	4.1	285
337	Prediction of sexual function after radical prostatectomy. <i>Cancer</i> , 2009, 115, 3150-3159.	4.1	33
338	Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 5680-5687.	4.1	61
339	Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: Results from a prostate cancer screening cohort of 1490 men. <i>International Journal of Urology</i> , 2009, 16, 91-95.	1.0	8
340	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. <i>International Journal of Urology</i> , 2009, 16, 526-529.	1.0	18
341	Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. <i>BJU International</i> , 2009, 103, 33-37.	2.5	75
342	Can nomograms be superior to other prediction tools?. <i>BJU International</i> , 2009, 103, 492-497.	2.5	108

#	ARTICLE	IF	CITATIONS
343	Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU International, 2009, 103, 889-893.	2.5	26
344	Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study. BJU International, 2009, 103, 597-602.	2.5	9
345	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU International, 2009, 103, 1359-1362.	2.5	67
346	A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU International, 2009, 103, 899-904.	2.5	37
347	Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU International, 2009, 103, 894-898.	2.5	47
348	Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy. BJU International, 2009, 103, 1632-1635.	2.5	44
349	A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU International, 2009, 103, 1496-1500.	2.5	118
350	Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU International, 2009, 103, 1368-1374.	2.5	61
351	Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU International, 2009, 104, 795-799.	2.5	18
352	External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU International, 2009, 104, 1661-1667.	2.5	19
353	External Validation of the Updated Partin Tables in a Cohort of French and Italian Men. International Journal of Radiation Oncology Biology Physics, 2009, 73, 347-352.	0.8	46
354	Multi-Institutional External Validation of Seminal Vesicle Invasion Nomograms: Head-to-Head Comparison of Gallina Nomogram Versus 2007 Partin Tables. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1461-1467.	0.8	15
355	Partial Versus Radical Nephrectomy in Patients With Adverse Clinical or Pathologic Characteristics. Urology, 2009, 73, 1300-1305.	1.0	87
356	Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma. Urology, 2009, 73, 342-346.	1.0	67
357	Sex Hormone-binding Globulin: A Novel Marker for Nodal Metastases Prediction in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection. Urology, 2009, 73, 850-855.	1.0	18
358	Effect of Body Mass Index on Histopathologic Parameters: Results of Large European Contemporary Consecutive Open Radical Prostatectomy Series. Urology, 2009, 73, 615-619.	1.0	30
359	Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort. Urology, 2009, 73, 1323-1327.	1.0	12
360	Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer. Urology, 2009, 73, 1087-1091.	1.0	102

#	ARTICLE	IF	CITATIONS
361	Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. <i>Urology</i> , 2009, 74, 373-377.	1.0	47
362	Partial Cystectomy Does Not Undermine Cancer Control in Appropriately Selected Patients With Urothelial Carcinoma of the Bladder: A Population-based Matched Analysis. <i>Urology</i> , 2009, 74, 858-864.	1.0	77
363	A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States. <i>Urology</i> , 2009, 74, 837-841.	1.0	25
364	Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?. <i>Urology</i> , 2009, 74, 842-845.	1.0	15
365	Benign Prostatic Hyperplasia and Its Aetiologies. <i>European Urology Supplements</i> , 2009, 8, 865-871.	0.1	96
366	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 907-913.	0.4	54
367	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 70-77.	0.4	131
368	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 459-465.	0.4	15
369	Development and External Validation of a Highly Accurate Nomogram for the Prediction of Perioperative Mortality After Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2009, 182, 626-632.	0.4	21
370	Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2009, 182, 2607-2612.	0.4	52
371	Independent Validation of a Model Predicting the Need for Packed Red Blood Cell Transfusion at Liver Transplantation. <i>Transplantation</i> , 2009, 88, 386-391.	1.0	38
372	Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. <i>Canadian Urological Association Journal</i> , 2009, 3, 13-21.	0.6	17
373	Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. <i>Cancer</i> , 2008, 113, 701-709.	4.1	86
374	Currently used criteria for active surveillance in men with low-risk prostate cancer. <i>Cancer</i> , 2008, 113, 2068-2072.	4.1	96
375	Mortality at 120 days after prostatic biopsy: A population-based study of 22,175 men. <i>International Journal of Cancer</i> , 2008, 123, 647-652.	5.1	44
376	A nomogram predicting metastatic progression after radical prostatectomy. <i>International Journal of Urology</i> , 2008, 15, 889-894.	1.0	12
377	High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. <i>BJU International</i> , 2008, 102, 463-467.	2.5	17
378	Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. <i>BJU International</i> , 2008, 102, 1610-1614.	2.5	29

#	ARTICLE	IF	CITATIONS
379	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 2008, 53, 794-802.	1.9	137
380	Radical Prostatectomy for Incidental (Stage T1aâ€“T1b) Prostate Cancer: Analysis of Predictors for Residual Disease and Biochemical Recurrence. <i>European Urology</i> , 2008, 54, 118-125.	1.9	61
381	Clinicians are Most Familiar with Nomograms and Rate their Clinical Usefulness Highest, Look-up Tables are Second Best. <i>European Urology</i> , 2008, 54, 958-959.	1.9	37
382	Reply to Michael Staehler's Letter to the Editor re: Pierre I Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. <i>Eur Urol</i> 2008;53:845-848. <i>European Urology</i> , 2008, 54, 951-953.	1.9	9
383	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2008, 54, 794-804.	1.9	61
384	Body Mass Index and its Association with Genitourinary Disorders in Men Undergoing Prostate Cancer Screening. <i>Journal of Sexual Medicine</i> , 2008, 5, 2141-2151.	0.6	10
385	Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer. <i>Urology</i> , 2008, 72, 1208-1211.	1.0	13
386	Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study. <i>Urology</i> , 2008, 72, 1090-1095.	1.0	43
387	External Validation of the Updated Partin Tables in a Cohort of North American Men. <i>Journal of Urology</i> , 2008, 180, 898-903.	0.4	36
388	SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1